Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680376 | 0.76 | KMT2A (0.35) | KMT2AKDM4ESIGMAR1 | |
| SCHEMBL10101627 | 0.74 | KMT2A (0.34) | KMT2AKDM4ESIGMAR1ALDH1A1GAA | |
| SCHEMBL2980091 | 0.74 | KMT2A (0.34) | KMT2AKDM4ESIGMAR1ALDH1A1GAA | |
| SCHEMBL6897806 | 0.74 | KMT2A (0.34) | KMT2AKDM4ESIGMAR1 | |
| SCHEMBL227850 | 0.73 | CYP3A4 (0.34) | CYP2D6CYP2C19 | |
| SCHEMBL5924166 | 0.72 | KDM4E (0.36) | KMT2AKDM4ESIGMAR1ALDH1A1GAA | |
| SCHEMBL9285442 | 0.72 | KMT2A (0.33) | KMT2AKDM4ESIGMAR1 | |
| SCHEMBL4667733 | 0.72 | TP53 (0.33) | KMT2AKDM4ESIGMAR1ALDH1A1GAA | |
| Bromide SCHEMBL9290759 | 0.71 | KDM4E (0.35) | KMT2AKDM4ESIGMAR1ALDH1A1GAA | |
| SCHEMBL28185302 | 0.70 | CYP2C9 (0.33) | CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences, S.R.L. (IT) | 2021-09-30 | — | — | US | disclosed |
| US-20190194214-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-06-27 | — | — | US | disclosed |
| US-10280176-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-05-07 | — | — | US | disclosed |
| US-20170190714-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-07-06 | — | — | US | disclosed |
| US-9637497-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | Nerviano Medical Sciences, S.R.L. (IT) | 2017-05-02 | — | — | US | disclosed |
| US-20170050972-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-02-23 | — | — | US | disclosed |
| EP-0316852-A2 | Inhibitors of nonenzymatic cross-linking | THE ROCKEFELLER UNIVERSITY (US) | 1989-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | KMT2A 1627/4885KDM4E 1031/4885SIGMAR1 3918/4885 |
| US-20190194214-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | KMT2A 1611/4885KDM4E 1015/4885SIGMAR1 3937/4885 |
| US-10280176-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | MAP3K5, MAP3K9, MAP4K2 | KMT2A 1611/4885KDM4E 1015/4885SIGMAR1 3937/4885 |
| US-20170190714-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | KMT2A 1611/4885KDM4E 1015/4885SIGMAR1 3937/4885 |
| US-20170050972-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | KMT2A 1611/4885KDM4E 1015/4885SIGMAR1 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.